Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Theriva Biologics ( (TOVX) ) has provided an update.
On October 20, 2025, Theriva Biologics presented expanded data from their VIRAGE Phase 2b trial at the ESMO 2025 Annual Congress. The trial evaluates the efficacy of VCN-01 combined with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Results indicate that VCN-01, when used with standard care, shows promising improvements in progression-free survival and overall response rates, potentially enhancing treatment outcomes for this aggressive cancer.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics, Inc. operates in the biotechnology industry, focusing on developing oncolytic adenoviruses for cancer treatment. Their primary product, VCN-01, is designed to target cancer cells with a dysfunctional RB1 pathway and enhance chemotherapy effectiveness.
Average Trading Volume: 4,590,963
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.04M
For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.